Prosight Management, LP reported 34 positions worth $552.02M for the quarter ended Jun 30, 2026. Its largest holding is Lakefront Biotherapeutics NV at 11.1% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | LKFT Lakefront Biotherapeutics NV | Healthcare | 2.04M | $61.26M | 11.1% | – | – | – | 3.1% |
| 2 | JANX Janux Therapeutics, Inc. | Healthcare | 3.80M | $58.44M | 10.59% | – | – | – | 6.04% |
| 3 | NKTR Nektar Therapeutics | Healthcare | 810.0K | $56.55M | 10.24% | – | – | – | 2.45% |
| 4 | BSX Boston Scientific Corp | Healthcare | 1.27M | $54.22M | 9.82% | – | – | – | 0.09% |
| 5 | STTK Shattuck Labs, Inc. | Healthcare | 5.96M | $41.35M | 7.49% | – | – | – | 4.59% |
| 6 | INSM INSMED Inc | Healthcare | 375.6K | $40.05M | 7.25% | – | – | – | 0.17% |
| 7 | ALNY Alnylam Pharmaceuticals, Inc. | Healthcare | 98.1K | $29.53M | 5.35% | – | – | – | 0.07% |
| 8 | SNDX Syndax Pharmaceuticals Inc | Healthcare | 1.20M | $26.23M | 4.75% | – | – | – | 1.35% |
| 9 | KURA Kura Oncology, Inc. | Healthcare | 2.02M | $22.18M | 4.02% | – | – | – | 2.27% |
| 10 | ALKS Alkermes plc. | Healthcare | 394.4K | $20.66M | 3.74% | – | – | – | 0.24% |
| 11 | IRTC iRhythm Holdings, Inc. | Healthcare | 165.5K | $19.69M | 3.57% | – | – | – | 0.5% |
| 12 | VEEV Veeva Systems Inc | Technology | 106.2K | $18.85M | 3.41% | – | – | – | 0.07% |
| 13 | ZYME Zymeworks Inc. | Healthcare | 674.4K | $17.63M | 3.19% | – | – | – | 0.92% |
| 14 | MLYS Mineralys Therapeutics, Inc. | Healthcare | 449.8K | $12.14M | 2.2% | – | – | – | 0.51% |
| 15 | ADCT ADC Therapeutics SA | Healthcare | 7.82M | $8.37M | 1.52% | – | – | – | 5.05% |
Tip. Select a row to see that position’s full history at Prosight Management.
As of its Q2 2026 13F filing, Prosight Management, LP’s five largest positions were Lakefront Biotherapeutics NV (LKFT) at 11.1%, Janux Therapeutics, Inc. (JANX) at 10.6%, Nektar Therapeutics (NKTR) at 10.2%, Boston Scientific Corp (BSX) at 9.8%, Shattuck Labs, Inc. (STTK) at 7.5% of the reported portfolio.
Prosight Management, LP reported a 13F portfolio worth $552.02M across 34 positions for Q2 2026.
From the Form 13F-HR reports Prosight Management, LP files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.